Početna stranicaSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Preth. zaklj. cijena
1.690,60 ₹
Dnevni raspon
1.681,10 ₹ - 1.727,50 ₹
Godišnji raspon
1.460,90 ₹ - 1.960,35 ₹
Tržišna kapitalizacija
4,04 bil. INR
Prosječna količina
2,79 mil.
P/E omjer
35,71
Prinos dividende
0,95 %
Glavno tržište vrijednosnica
NSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (INR) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 129,59 mlr. | 8,14 % |
Operativni troškovi | 75,61 mlr. | 20,16 % |
Neto dohodak | 21,50 mlr. | −19,01 % |
Neto profitabilnost | 16,59 | −25,10 % |
Zarada po dionici | 10,01 | −13,02 % |
EBITDA | 34,05 mlr. | 9,13 % |
Efektivna porezna stopa | 33,68 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (INR) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 249,88 mlr. | 30,89 % |
Ukupna imovina | 921,01 mlr. | 7,77 % |
Ukupne obveze | 196,15 mlr. | 6,85 % |
Ukupni kapital | 724,86 mlr. | — |
Dionice u optjecaju | 2,39 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 5,59 | — |
Povrat imovine | — | — |
Povrat kapitala | 9,40 % | — |
Tok novca
Neto promjena novca
| (INR) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 21,50 mlr. | −19,01 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Osnovano
1983
Sjedište
Web-lokacija
Zaposlenici
43.000
